Delek Group’s Novartis NVS Stock Holding History

Delek Group’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-76,714	Closed	-$6.58M	–	233
2019 Q1	$6.58M	Hold	76,714	–	–	0.27%	106
2018 Q4	$6.06M	Sell	76,714 -22,320	-23%	-$1.74M	0.28%	114
2018 Q3	$7.6M	Sell	99,034 -27,677	-22%	-$2.05M	0.32%	108
2018 Q2	$8.94M	Hold	126,711	–	–	0.38%	93
2018 Q1	$9.42M	Buy	126,711 +26,784	+27%	+$2.04M	0.48%	80
2017 Q4	$7.66M	Buy	+99,927	New	+$7.54M	0.41%	90

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Delek Group's NVS Position: Q2 2019 in Review

Delek Group sold out of Novartis (NVS) in Q2 2019, closing a stake of 76,714 shares — an estimated $6.58M sold.

Delek Group first reported a position in NVS in Q4 2017 and held it in 6 quarters. The position peaked at $9.42M in Q1 2018. 1,094 funds tracked by Wall St. Rank hold NVS as of Q2 2019.

Delek Group reported no remaining Novartis position as of Q2 2019 after selling out during the quarter.
Delek Group sold 76,714 Novartis shares in Q2 2019, an estimated $6.58M.
Delek Group first reported a position in Novartis in Q4 2017 and held it in 6 quarters.
Delek Group's Novartis position peaked at $9.42M in Q1 2018.
1,094 funds tracked by Wall St. Rank held Novartis as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.